Twist Bioscience (TWST) Income from Continuing Operations (2017 - 2026)
Twist Bioscience has reported Income from Continuing Operations over the past 10 years, most recently at 44021000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 11.86% to 44021000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 81266000.0 through Mar 2026, up 57.49% year-over-year, with the annual reading at 77651000.0 for FY2025, 62.8% up from the prior year.
- Income from Continuing Operations was 44021000.0 for Q1 2026 at Twist Bioscience, down from 30507000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 20381000.0 in Q2 2025 and troughed at 85580000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 44021000.0 (2026), against an average of 43405882.35.
- Year-over-year, Income from Continuing Operations plummeted 59.99% in 2022 and then surged 123.82% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 41824000.0 in 2022, then fell by 2.83% to 43008000.0 in 2023, then grew by 26.53% to 31597000.0 in 2024, then increased by 3.45% to 30507000.0 in 2025, then plummeted by 44.3% to 44021000.0 in 2026.
- Per Business Quant, the three most recent readings for TWST's Income from Continuing Operations are 44021000.0 (Q1 2026), 30507000.0 (Q4 2025), and 27119000.0 (Q3 2025).